Experimental pill enlicitide significantly lowers bad cholesterol

utsouthwestern.edu

An experimental pill, enlicitide, dramatically reduced "bad" cholesterol by up to 60% in a phase three trial. The novel oral medication, published in The New England Journal of Medicine, could significantly lower heart attack and stroke risk for millions if approved by the FDA. This development builds on decades of cholesterol research at UT Southwestern, potentially overcoming barriers associated with injectable cholesterol-lowering drugs.


With a significance score of 5.6, this news ranks in the top 0.6% of today's 30225 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: